Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

SIMPLE SUMMARY: Therapeutic options for the treatment of men with metastatic castration-resistant prostate cancer are limited. Docetaxel—a taxane-based chemotherapeutic agent—was the first treatment to demonstrate significant efficacy in the treatment of this disease. However, responses to docetaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Thiago S., Iglesias-Gato, Diego, Souza, Luciano D. O., Stenvang, Jan, Lima, Diego S., Røder, Martin A., Brasso, Klaus, Moreira, José M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998254/
https://www.ncbi.nlm.nih.gov/pubmed/33799432
http://dx.doi.org/10.3390/cancers13061290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998254/
https://www.ncbi.nlm.nih.gov/pubmed/33799432
http://dx.doi.org/10.3390/cancers13061290

Ejemplares similares